



NDA 19774/S-023

SUPPLEMENT APPROVAL

Ferring Pharmaceuticals, Inc.
Attention: John C. Kim, RPh, JD
Senior Director, Regulatory Affairs
4 Gatehall Drive, Third Floor
Parsippany, NJ 07054

Dear Mr. Kim:

Please refer to your Supplemental New Drug Application (sNDA) dated March 8, 2011, received March 9, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for TEV-TROPIN (somatropin [rDNA origin]) for injection.

This "Prior Approval" supplemental new drug application provides for a revised package insert submitted in response to our October 7, 2010 supplement request letter. In this letter, we requested revisions to the WARNINGS and PRECAUTIONS sections pertaining to pancreatitis. During our review of the labeling, we made additional revisions regarding diabetes mellitus (PRECAUTIONS and ADVERSE REACTIONS). These revisions were requested of all marketed somatropin products. Lastly, the WARNINGS section was updated to include information regarding benzyl alcohol, and the ADVERSE REACTIONS section was updated to include information on potential immunogenicity of therapeutic proteins.

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kati Johnson, Regulatory Project Manager, at (301) 796-1234.

Sincerely,

{See appended electronic signature page}

Mary H. Parks, MD
Director
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARY H PARKS
07/19/2011